Literature DB >> 19239592

Chronic kidney disease: appropriateness of therapeutic management and associated factors in the AVENIR study.

Nathalie Thilly1, Stéphanie Boini, Michèle Kessler, Serge Briançon, Luc Frimat.   

Abstract

RATIONALE, AIMS AND
OBJECTIVES: The nephrology literature contains little information about the global patterns of medication used in the management of patients with chronic kidney disease (CKD). This study aims to evaluate the appropriateness of nephrological therapeutic management of CKD patients compared with current guidelines and to investigate associations between patient characteristics and the quality of therapeutic management.
METHODS: All adult CKD patients who were starting dialysis in Lorraine (France) between 1 January 2005 and 31 December 2006 and who had been referred to a nephrologist no less than 1 month previously were enrolled. Demographic, clinical, biological and therapeutic data were collected retrospectively from medical records covering the period from the first nephrology consultation to initiation of dialysis. Outcomes of interest were the appropriateness of the therapeutic management of five aspects of CKD: hypertension/proteinuria, anaemia, bone disease, metabolic acidosis and dyslipidemia. Therapeutic care was given a global rating (high, moderate or poor), depending on the number of aspects being managed appropriately. Relationships between the global rating and demographic and clinical characteristics of patients were explored.
RESULTS: During predialysis nephrology follow-up, 93.1% of the 420 patients enrolled were receiving antihypertensive therapy; 67.1% were taking a renin-angiotensin system inhibitor. Other prescriptions included: erythropoiesis-stimulating agents (67.4%), iron (48.3%), phosphate binders (38.1%), vitamin D (21.1%), bicarbonates (15.5%) and statins (36.2%). Hypertension/proteinuria was managed appropriately in 72.4% of cases, anaemia in 56.2%, bone disease in 16.7%, metabolic acidosis in 60.2% and dyslipidemia in 61.4%. The global quality of care was high in 22.1% of cases, moderate in 65.7% and poor in 12.2%. After adjustment, the more nephrology consultations a patient had before dialysis, the higher the quality of his or her care.
CONCLUSION: The quality of therapeutic care delivered to CKD patients in nephrology setting was suboptimal when assessed in terms of adherence to guidelines.

Entities:  

Mesh:

Year:  2009        PMID: 19239592     DOI: 10.1111/j.1365-2753.2008.00965.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  7 in total

1.  User Requirements for a Chronic Kidney Disease Clinical Decision Support Tool to Promote Timely Referral.

Authors:  Joy Gulla; Pamela M Neri; David W Bates; Lipika Samal
Journal:  Int J Med Inform       Date:  2017-02-04       Impact factor: 4.046

Review 2.  Type 2 translational research for CKD.

Authors:  Katherine R Tuttle; Delphine S Tuot; Cynthia L Corbett; Stephen M Setter; Neil R Powe
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-25       Impact factor: 8.237

3.  Predialysis therapeutic care and health-related quality of life at dialysis onset (The pharmacoepidemiologic AVENIR study).

Authors:  Stephanie Boini; Luc Frimat; Michele Kessler; Serge Briançon; Nathalie Thilly
Journal:  Health Qual Life Outcomes       Date:  2011-01-24       Impact factor: 3.186

4.  Characterizing pre-dialysis care in the era of eGFR reporting: a cohort study.

Authors:  Khaled Abdel-Kader; Gary S Fischer; James R Johnston; Chen Gu; Charity G Moore; Mark L Unruh
Journal:  BMC Nephrol       Date:  2011-03-15       Impact factor: 2.388

5.  Course of chronic kidney disease in French patients.

Authors:  Nicolas Janus; Vincent Launay-Vacher; Laurent Juillard; Gilbert Deray; Thierry Hannedouche; Myriam Isnard-Rouchon; Stéphane Burtey; Philippe Vanhille; Jean-Paul Ortiz; Gérard Janin; Philippe Nicoud; Malik Touam; Maurice Laville
Journal:  Clin Kidney J       Date:  2016-09-23

6.  The impact of renal protection clinics on prescription of and adherence to cardioprotective drug therapy in chronic kidney disease patients.

Authors:  Fanny Lepeytre; Héloise Cardinal; Lorraine Fradette; Jacobien Verhave; Marc Dorais; Jacques LeLorier; Vincent Pichette; François Madore
Journal:  Clin Kidney J       Date:  2017-02-18

7.  Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis.

Authors:  Lipika Samal; Adam Wright; Sushrut S Waikar; Jeffrey A Linder
Journal:  BMC Nephrol       Date:  2015-10-12       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.